Skin care composition containing pinane glycol and aminobutyric acid and application thereof

Abstract

The invention provides a skin care composition and application thereof. The skin care composition comprises the following components in a physiologically acceptable medium: (a) pinane glycol; and (b) aminobutyric acid, wherein the mass ratio of pinane diol to aminobutyric acid is 1: (0.5-55). The pinanediol and the gamma-aminobutyric acid have a synergistic interaction effect after being compounded, and the expression quantity of the type I collagen in the skin can be remarkably improved, so that the synthesis of the type I collagen in the skin can be remarkably promoted under the condition that a relatively small amount of pinanediol and gamma-aminobutyric acid are used. Meanwhile, the problems of irritation, high cost and the like caused by too high dosage of active matters are avoided, and the goals of low cost, high efficacy and high safety are achieved.

Description

Technical Field

[0001] The present application relates to the technical field of cosmetics, and in particular to a skin care composition comprising pinanediol and aminobutyric acid and uses thereof. Background Art

[0002] Collagen is an abundant protein that exists in many tissues such as skin, bones, tendons, cartilage and blood vessels. It performs various functions through the high-level structure formed by protein polymerization and plays an important role in the life activities of cells, tissues and organs. Among them, type I collagen accounts for more than 80% of the human body's collagen and plays a role in supporting the skin structure. In the skin, type I collagen is the main component of the dermis, constituting collagen fibers, providing elasticity and firmness to the skin. With age, the synthesis rate of type I collagen decreases, while the degradation rate increases, resulting in the breakage and reduction of collagen fibers, which causes aging phenomena such as sagging skin, wrinkles, and dryness. Therefore, it is necessary to restart collagen synthesis in the body to effectively resist skin aging (especially in the dermis). Summary of the invention

[0003] After extensive research, the inventors found that the combination of pinanediol and γ-aminobutyric acid has a synergistic effect in promoting the expression of type I collagen in the skin, thereby effectively resisting skin aging, especially dermal aging.

[0004] The specific technical solutions of this application are as follows:

[0005] 1. A skin care composition comprising the following components in a physiologically acceptable medium:

[0006] (a) pinanediol; and

[0007] (b) aminobutyric acid,

[0008] The mass ratio of pinanediol to aminobutyric acid is 1:(0.5-55).

[0009] 2. The skin care composition according to item 1, wherein the mass ratio of pinanediol to aminobutyric acid is 1:(1-50).

[0010] 3. Use of the skin care composition described in item 1 or 2 for increasing the expression of type I collagen in the skin.

[0011] 4. Use of the skin care composition according to item 1 or 2 for improving skin elasticity and firmness.

[0012] 5. Use of the skin care composition described in item 1 or 2 in resisting and / or alleviating skin aging.

[0013] 6. Use of the skin care composition described in item 1 or 2 in the preparation of cosmetics.

[0014] 7. Use of a combination of pinanediol and aminobutyric acid in increasing the expression of type I collagen in the skin.

[0015] 8. Use of a combination of pinanediol and aminobutyric acid for improving skin elasticity and firmness.

[0016] 9. Use of a combination of pinanediol and aminobutyric acid in resisting and / or alleviating skin aging.

[0017] 10. The use according to any one of items 7 to 9, wherein the mass ratio of pinanediol to aminobutyric acid is 1:(0.5-55).

[0018] Effects of the Invention

[0019] The present invention has a synergistic effect after compounding pinanediol and γ-aminobutyric acid, which can significantly increase the expression of type I collagen in the skin, thereby significantly promoting the synthesis of type I collagen in the skin when using a relatively small amount of pinanediol and γ-aminobutyric acid. At the same time, it avoids the problems of irritation and high cost caused by excessive use of active ingredients, and achieves the goals of low cost, high efficacy and high safety. DETAILED DESCRIPTION

[0020] The present application is described in detail below in conjunction with the described embodiments. Although specific embodiments of the present application are shown, it should be understood that the present application can be implemented in various forms and should not be limited by the embodiments set forth herein. On the contrary, these embodiments are provided to enable a more thorough understanding of the present application and to enable the scope of the present application to be fully communicated to those skilled in the art.

[0021] It should be noted that certain words are used in the specification and claims to refer to specific components. Those skilled in the art should understand that technicians may use different nouns to refer to the same component. This specification and claims do not use the difference in nouns as a way to distinguish components, but use the functional differences of components as the criterion for distinction. As mentioned throughout the specification and claims, "including" or "comprising" are open-ended terms and should be interpreted as "including but not limited to". The subsequent description of the specification is a preferred embodiment of the present application, but the description is based on the general principles of the specification and is not intended to limit the scope of the present application. The scope of protection of the present application shall be determined by the attached claims.

[0022] The present application provides a skin care composition comprising the following components in a physiologically acceptable medium:

[0023] (a) pinanediol; and

[0024] (b) aminobutyric acid,

[0025] The mass ratio of pinanediol to aminobutyric acid is 1:(0.5-55).

[0026] In some preferred embodiments, the mass ratio of pinanediol to aminobutyric acid is 1:(1-50), for example, the mass ratio of pinanediol to aminobutyric acid (m 蒎烷二醇 :m 氨基丁酸 ) can be 1:0.5, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:11, 1:12, 1:13, 1:14, 1:15, 1:16, 1:17, 1:18, 1:19, 1:20, 1:21, 1:22, 1:23, 1:24, 1:25, 1:26, 1:27, 1:28 28, 1:29, 1:30, 1:31, 1:32, 1:33, 1:34, 1:35, 1:36, 1:37, 1:38, 1:39, 1:40, 1:41, 1:42, 1:43, 1:44, 1:45, 1:46, 1:47, 1:48, 1:49, 1:50, 1:51, 1:52, 1:53, 1:54, 1:55, etc.

[0027] The amounts of pinanediol and aminobutyric acid to be used according to the present invention may vary within wide limits to determine suitable amounts, depending on the desired dermatological effect.

[0028] In some embodiments, the pinanediol is present in an amount of 0.0001-2% by mass in the skin care composition.

[0029] For example, in terms of mass percentage in the skin care composition, the pinanediol may be 0.0001%, 0.0002%, 0.0003%, 0.0004%, 0.0005%, 0.0006%, 0.0007%, 0.0008%, 0.0009%, 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006 ... .006%, 0.007%, 0.008%, 0.009%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 1.5%, 2%, etc.

[0030] In some embodiments, the aminobutyric acid is 0.0001-2% by mass in the skin care composition.

[0031] For example, in terms of mass percentage in the skin care composition, the aminobutyric acid may be 0.0001%, 0.0002%, 0.0003%, 0.0004%, 0.0005%, 0.0006%, 0.0007%, 0.0008%, 0.0009%, 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006 ... .006%, 0.007%, 0.008%, 0.009%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 1.5%, 2%, etc.

[0032] Pinanediol, INCI: PINANEDIOL.

[0033] The chemical formula of GABA (γ-aminobutyric acid) is C 4 H 9 NO 2 , also known as 4-aminobutyric acid, INCI: AMINOBUTYRIC ACID.

[0034] As physiologically acceptable media, their composition, usage amount, etc. can be selected by those skilled in the art according to their knowledge and the type of application scenario required.

[0035] In the present application, the physiologically acceptable medium is such as solvents, UV filters, antioxidants, emulsifiers, fillers, colorants, preservatives, fragrances, skin care active agents such as moisturizers, anti-aging agents, whitening agents and mixtures thereof.

[0036] Examples of the solvent include water, oils and fats, hexylene glycol, butanediol, and 1,3-propylene glycol.

[0037] As UV filters, for example, benzophenone, 4-butylmethoxydibenzoylmethane, octocrylene, ethylhexyl methoxycinnamate, ethylhexyl salicylate, phenylbenzimidazole sulfonic acid or homosalate may be used.

[0038] As the antioxidant, for example, tocopherol acetate, BHT, BHA and the like are mentioned.

[0039] Examples of the emulsifier include anionic emulsifiers, cationic emulsifiers, amphoteric emulsifiers, and nonionic emulsifiers.

[0040] As fillers, for example, silicon dioxide, mica, kaolin, oxides of zinc and titanium of natural or synthetic origin; calcium carbonate, magnesium carbonate and magnesium hydrogen carbonate; zinc stearate, magnesium stearate or lithium stearate, zinc laurate, magnesium myristate and the like.

[0041] Examples of the coloring agent include iron oxide, carbon black, titanium dioxide, zinc oxide, cochineal, carotene, and chlorophyll.

[0042] Examples of the preservative include phenoxyethanol, benzyl alcohol, benzoic acid, sorbic acid, and imidazolidinyl urea.

[0043] Examples of the flavor include citronellol and tricyclodecenyl acetate.

[0044] Examples of the moisturizer include mannitol, sodium hyaluronate, lactic acid, glycerin, urea, and propylene glycol.

[0045] As anti-aging agents, for example, retinol, phytosterols, ceramide, recombinant type I collagen, recombinant type II collagen, recombinant type IV collagen and recombinant type XVII collagen.

[0046] As whitening agents, there are arbutin, phenethylresorcinol, ascorbic acid and its derivatives and the like.

[0047] The present application provides the use of the above-mentioned skin care composition in increasing the expression of type I collagen in the skin.

[0048] The pinanediol and pinanediol in the skin care composition work synergistically to increase the expression of type I collagen in the skin.

[0049] The present application provides the use of the above-mentioned skin care composition in improving skin elasticity and firmness.

[0050] The present application provides use of the above-mentioned skin care combination in resisting and / or alleviating skin aging.

[0051] The skin care composition described in the present application can effectively resist skin aging because it can increase the expression of type I collagen in the skin, thereby improving skin elasticity and skin firmness, and can resist and / or alleviate skin aging.

[0052] The present application provides use of the above-mentioned skin care composition in preparing cosmetics.

[0053] The present application provides the use of a combination of pinanediol and aminobutyric acid in increasing the expression of type I collagen in the skin.

[0054] In some embodiments, the mass ratio of pinanediol to aminobutyric acid is 1:(0.5-55), preferably 1:(1-50).

[0055] The present application provides the use of a combination of pinanediol and aminobutyric acid in improving skin elasticity and firmness.

[0056] In some embodiments, the mass ratio of pinanediol to aminobutyric acid is 1:(0.5-55), preferably 1:(1-50).

[0057] The present application provides use of a combination of pinanediol and aminobutyric acid in resisting and / or alleviating skin aging.

[0058] In some embodiments, the mass ratio of pinanediol to aminobutyric acid is 1:(0.5-55), preferably 1:(1-50).

[0059] The composition described in the present application is applied in the field of beauty and skin care to achieve the technical effects of the present application for non-therapeutic purposes.

[0060] Example

[0061] The present application provides a general and / or specific description of the materials and test methods used in the experiments. In the following examples, unless otherwise specified, % represents wt%, i.e., weight percentage. The reagents or instruments used without indicating the manufacturer are all conventional reagent products that can be obtained commercially. Among them, the content of pinanediol is about 100%, which is purchased from Shanghai Xianding Biotechnology Co., Ltd., and aminobutyric acid (aminobutyric acid content is about 100%) is purchased from Huaxi Biotechnology (Tianjin) Co., Ltd.

[0062] Experimental Example 1 Cytotoxicity Test

[0063] 1. Experimental Materials

[0064] Human fibroblasts (Beina Biotechnology BNCC358600), cell culture medium: DMEM-H complete medium (containing 10% FBS): 90% DMEM-H + 10% FBS (fetal bovine serum), MTT (Sigma), DMSO (Sinopharm), trypsin-EDTA (0.25%).

[0065] 2. Experimental Methods

[0066] The experiment set up a zero-adjustment group, a control group, a positive control group and a sample group.

[0067] Sample group: 8 concentration gradients of pinanediol and aminobutyric acid were set as shown in Tables 1 and 2 respectively (preparation method: weigh 0.1 g of pinanediol sample, dissolve in 1 mL of anhydrous ethanol, prepare a 10% stock solution, and dilute with PBS; weigh 0.1 g of aminobutyric acid sample, dissolve in 1 mL of PBS, prepare a 10% stock solution, and dilute with PBS);

[0068] Control group: cell culture medium;

[0069] Positive control group: cell culture medium containing 10% DMSO;

[0070] Zero adjustment group: cell culture medium.

[0071] Three replicate wells were set up under each concentration gradient, and the drug was administered when the plating rate of human fibroblasts in the 96-well plate reached 40% to 60%. 200 μL of cell culture medium containing 10% PBS was added to each well of the control group; 200 μL of cell culture medium containing 10% DMSO was added to each well of the positive control group; 200 μL of cell culture medium containing samples of corresponding concentrations was added to each well of the sample group; there was no cell inoculation in the zero adjustment group, and only 200 μL of cell culture medium was added. After the drug administration was completed, the 96-well plate was placed in an incubator (37°C, 5% CO 2 ) were cultured. After the cells were incubated for 24 hours, the supernatant was discarded, MTT working solution (0.5 mg / mL) was added, and the cells were incubated at 37°C in the dark for 4 hours. After the incubation, the supernatant was discarded, 100 μL DMSO was added to each well, and the OD value was read at 490 nm. The cell survival rate was calculated using the following formula: Cell survival rate (%) = average absorbance (OD value) of the test group / average absorbance (OD value) of the blank control group × 100%.

[0072] When the cell survival rate was ≥90%, there was no obvious cytotoxicity, and the concentration without cytotoxicity was selected for the next test.

[0073] The results are shown in Table 1-2.

[0074] Table 1 Pinanediol cytotoxicity results

[0075]

[0076] Table 2 GABA cytotoxicity results

[0077]

[0078]

[0079] As can be seen from Table 1-2, pinanediol has no cytotoxicity at a concentration below 0.03% and aminobutyric acid has no cytotoxicity at a concentration below 0.5%.

[0080] Experimental Example 2 Type I collagen gene expression test

[0081] 1. Experimental Materials

[0082] Penicillin-streptomycin, trypsin-EDTA (0.25%), phosphate buffered saline (PBS), total RNA extraction kit for cultured cells / bacteria (Biorigin (BN12061), First strand cDNA Synthesis Kit (Biorigin (BN12008), Fast Super qPCR Master Mix (Biorigin (BN12028), human skin fibroblasts (source: Beina (BNCC358600)), cell culture medium: DMEM-H complete medium (containing 10% FBS): 90% DMEM-H + 10% FBS (fetal bovine serum), DMSO (Sinopharm)

[0083] 2. Experimental Principle

[0084] Human skin fibroblasts were used as the research object, UVB stimulation was used to establish an in vitro cell model, and the relative expression of type I collagen gene in cells was detected by q-PCR detection technology to explore the collagen-promoting effect of pinanediol, γ-aminobutyric acid and the combination. Fibroblasts synthesize and secrete collagen and elastin, generate collagen fibers, reticular fibers and elastic fibers, and also synthesize and secrete matrix components such as glycosaminoglycans and glycoproteins. In the skin, the content of type I collagen accounts for about 70%, while type III collagen accounts for 30%. The appearance of skin wrinkles is closely related to the normal synthesis and expression of collagen. The upregulation rate of type I collagen content after administration was determined to evaluate the efficacy of the test product in promoting collagen.

[0085] 3. Experimental Methods

[0086] The experiment set up model control group, normal control group and sample group.

[0087] Model control group: cell culture medium;

[0088] Normal control group: cell culture medium;

[0089] Sample set:

[0090] Pinanediol: weigh 0.1 g sample and dissolve it in 1 mL DMSO to prepare a 10% stock solution;

[0091] GABA: weigh 0.1 g sample and dissolve it in 1 mL PBS to prepare a 10% stock solution;

[0092] The samples of Examples 1-8 and Comparative Examples 1-6 were prepared using cell culture medium according to Table 3.

[0093] Table 3

[0094]

[0095]

[0096] Human skin fibroblasts were seeded in 6-well plates (3×10 5 / well) at 37°C, 5% CO 2Incubate for 24 hours; after the incubation, remove the cell culture medium, wash with PBS 1-2 times, and then irradiate the sample group and the model control group with UVB (120mJ / cm 2 ); After the modeling was completed, the normal control group and the model control group were replaced with cell culture medium, and the samples of Examples 1-8 and Comparative Examples 1-6 were added to the sample wells and continued at 37°C, 5% CO 2 After incubation for 24 h, total RNA was extracted from each experimental group, cDNA was synthesized, and q-PCR was used to detect the gene expression of β-actin and target genes.

[0097] 4. Statistical Analysis of Results

[0098] β-actin was used as the internal reference for gene expression to calculate the relative RNA expression of the target gene.

[0099] Relative RNA expression = 2^ΔΔC(t)

[0100]

[0101] ΔC(t)=C(t) 目的基因 -C(t) β-actin

[0102] All experiments were repeated three times and the T.TEST test was used. The difference was considered statistically significant when P-value < 0.05. The results are shown in Table 3.

[0103] If the effect of the combination is greater than that of a single substance, and P < 0.05, the effects of the two components can be considered synergistic; if the effect of the combination is weaker than that of a single substance, and P < 0.05, the effects of the two components can be considered antagonistic; if P > 0.05, the effects of the two components can be considered additive.

[0104] Table 3

[0105]

[0106]

[0107] It can be seen from the above table that the pinanediol and aminobutyric acid in the composition described in the example work synergistically to significantly increase the expression level of type I collagen gene.

[0108] The above is only the preferred embodiment of the present application, and does not limit the present application in other forms. Any technician familiar with the profession may use the above disclosed technical content to change or modify it into an equivalent embodiment with equivalent changes. However, any simple modification, equivalent change and modification made to the above embodiment based on the technical essence of the present application without departing from the technical solution of the present application still falls within the protection scope of the technical solution of the present application.

Claims

1. A skin care composition comprising the following components in a physiologically acceptable medium: (a) pinanediol; and (b) aminobutyric acid, The mass ratio of pinanediol to aminobutyric acid is 1:(0.5-55).

2. The skin care composition according to claim 1, wherein The mass ratio of pinanediol to aminobutyric acid is 1:(1-50).

3. Use of the skin care composition according to claim 1 or 2 for increasing the expression of type I collagen in the skin.

4. Use of the skin care composition according to claim 1 or 2 for improving skin elasticity and firmness.

5. Use of the skin care composition according to claim 1 or 2 in resisting and / or alleviating skin aging.

6. Use of the skin care composition according to claim 1 or 2 in the preparation of cosmetics.

7. Use of a combination of pinanediol and aminobutyric acid in increasing the expression of type I collagen in the skin.

8. Use of a combination of pinanediol and aminobutyric acid for improving skin elasticity and firmness.

9. Use of a combination of pinanediol and aminobutyric acid in resisting and / or alleviating skin aging.

10. The use according to any one of claims 7 to 9, wherein The mass ratio of pinanediol to aminobutyric acid is 1:(0.5-55).

Images